Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: Results after 5 years of therapy

被引：0

作者：

Hadziyannis, S

Tassopoulos, N

Chang, TT

Heathcote, J

Kitis, G

Rizzetto, M

Marcellin, P

Lim, SG

Goodman, Z

Arterburn, S

Ma, J

Xiong, S

Borroto-Esoda, K

Brosgart, C

Currie, G

机构：

[1] Henry Dunant Hosp, Athens 70101, Greece

[2] Western Attica Gen Hosp, Athens, M5T 2S8, Greece

[3] Natl Cheng Kung Univ, Tainan, Taiwan

[4] Toronto Western Hosp, Toronto, ON, Canada

[5] Georgios Papanikolaou Dist Hosp, Thessaloniki, Greece

[6] Azienda Osped San Giovanni Battista, Turin 117548, Italy

[7] Hop Beaujon, Clichy, 20306, France

[8] Natl Univ Singapore Hosp, Singapore, 94404, Singapore

[9] Armed Forces Inst Pathol, Washington, DC USA

[10] Gilead Sci Inc, Foster City, CA USA

[11] Gilead Sci Inc, Durham, NC USA

来源：

HEPATOLOGY | 2005年 / 42卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：754A / 754A

页数：1

共 50 条

[31] Long-term entecavir (ETV) therapy improves liver stiffness measurements (LSMs) in patients with HBeAg-negative chronic hepatitis B (CHB)
Papatheodoridis, George V.
Goulis, Ioannis
Manolakopoulos, Spilios
Margariti, Katerina
Exarchos, Xenofon
Kokkonis, George
Papaioannou, Christos
Akriviadis, Evangelos A.
[J]. HEPATOLOGY, 2012, 56 : 380A - 380A
[32] Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B
Lee, Jung Min
Park, Jun Yong
Kim, Do Young
Nguyen, Tin
Hong, Sun Pyo
Kim, Soo Ok
Chon, Chae Yoon
Han, Kwang-Hyub
Ahn, Sang Hoon
[J]. ANTIVIRAL THERAPY, 2010, 15 (02) : 235 - 241
[33] LONG-TERM ADEFOVIR DIPIVOXIL MONOTHERAPY FOR UP TO 5 YEARS IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B
Lee, Jung Min
Park, Jun Yong
Kim, Do Young
Nguyen, Tin
Hong, Sunpyo
Lee, Kwan Sik
Moon, Byung Soo
Han, Kwang-Hyub
Chon, Chae Yoon
Moon, Young Myoung
Ahn, Sang Hoon
[J]. HEPATOLOGY, 2009, 50 (04) : 504A - 504A
[34] Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B
Kim, D. Y.
Lee, J. M.
Ahn, S. H.
Lee, Y. C.
Lee, D. K.
Chung, J. B.
Chon, C. Y.
Han, K-H
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A176 - A176
[35] Long-term (96 weeks) adefovir dipivoxil in HBeAg negative chronic hepatitis results in significant virological, biochemical and histological improvement.
Hadziyannis, S
Tassopoulos, N
Heathcote, E
Chang, TT
Kitis, G
Rizzeto, M
Marcellin, P
Lim, SG
Chen, SS
Wulfsohn, M
Xiong, S
James, C
Currie, G
Brosgart, C
[J]. HEPATOLOGY, 2003, 38 (04) : 273A - 273A
[36] Long-term follow-up after initial response to interferon therapy in patients with HBeAg-negative chronic hepatitis B.
Papatheodoridis, GV
Manesis, E
Hadziuannis, SJ
[J]. HEPATOLOGY, 2000, 32 (04) : 378A - 378A
[37] Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B
Papatheodoridis, GV
Petraki, K
Cholongitas, E
Kanta, E
Ketikoglou, I
Manesis, EK
[J]. JOURNAL OF VIRAL HEPATITIS, 2005, 12 (02) : 199 - 206
[38] Cost-effectiveness of two oral antiviral therapies, lamivudine and adefovir dipivoxil of HBeAg-negative chronic hepatitis B
Buti, M
Casado, MA
Calleja, JL
Salmerón, J
Aguilar, J
Rueda, M
Esteban, R
[J]. JOURNAL OF HEPATOLOGY, 2005, 42 : 172 - 172
[39] Efficacy of the treatment of HBeAg-negative chronic hepatitis B patients with lamivudine: Results of 12 month therapy
Seliverstova, T
Isakov, V
Bogomolov, P
Mironova, O
Pavlova, T
Tsodikov, G
Guschin, A
[J]. HEPATOLOGY, 2002, 36 (04) : 637A - 637A
[40] Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients
Borroto-Esoda, Katyna
Arterburn, Sarah
Snow, Amdrea
Chuck, Steven
Hadziyannis, Stefanos
Locamini, Stephen
Zoulim, Fabien
Pawlotsky, Jean-Michel
[J]. GASTROENTEROLOGY, 2006, 130 (04) : A764 - A765

← 1 2 3 4 5 →